2-Methoxyestradiol (2-ME 2 ) is a novel anticancer agent because of its ability to potentiate apoptotic cell death and inhibit cancer cell growth and angiogenesis. The modes of action of this agent, however, have not yet been fully elucidated. In our study, we have investigated whether 2-ME2 is able
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth
✍ Scribed by Frederic Amant; Mona-Liza Lottering; Annie Joubert; Veneesha Thaver; Ignace Vergote; B.G Lindeque
- Book ID
- 114101690
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 396 KB
- Volume
- 91
- Category
- Article
- ISSN
- 0090-8258
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract 2‐Methoxyestradiol (2‐ME), an endogenous metabolite of 17β‐estradiol, is present in human blood and urine. Here we show for the first time that 2‐ME significantly inhibited the growth of normal prostate epithelial cells and androgen‐dependent LNCaP and androgen‐independent DU145 prostat
## Abstract The cardiovascular benefits of statins, including atorvastatin (ATV), have been reported to be gender‐dependent, but the underlying mechanism is unclear. In this study we examine whether estrogen and its metabolite, 2‐methoxyestradiol (2ME), affect the rounding response of human vascula
## Abstract 2‐Methoxyestradiol, a well‐known nonpolar endogenous metabolite of 17β‐estradiol, has been shown to selectively induce apoptosis in a number of cancer cell lines, but not in normal cells. The mechanism of 2‐methoxyestradiol‐induced apoptosis appears to vary considerably in different cel